Melatonin treatment improves primary progressive multiple sclerosis: a case report

被引:50
|
作者
Lopez-Gonzalez, Antonio [1 ,2 ]
Alvarez-Sanchez, Nuria [3 ]
Lardone, Patricia J. [3 ,4 ]
Cruz-Chamorro, Ivan [3 ,4 ]
Martinez-Lopez, Alicia [3 ]
Guerrero, Juan M. [3 ,4 ,5 ]
Reiter, Russel J. [6 ]
Carrillo-Vico, Antonio [3 ,4 ]
机构
[1] Virgen Macarena Univ Hosp, Dept Neurosurg, Seville, Spain
[2] Virgen del Rocio Univ Hosp, Dept Neurosurg, Seville, Spain
[3] Univ Seville, CSIC, Virgen del Rocio Univ Hosp, Inst Biomed Seville IBiS, Seville 41013, Spain
[4] Univ Seville, Sch Med, Dept Med Biochem Mol Biol & Immunol, Seville 41013, Spain
[5] Virgen del Rocio Univ Hosp, Dept Clin Biochem, Seville, Spain
[6] UT Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX USA
关键词
melatonin; multiple sclerosis; primary progressive multiple sclerosis; OXIDATIVE DAMAGE; NATURAL-HISTORY; NERVOUS-SYSTEM; EXPRESSION; ANTIOXIDANT; PREVALENCE; CELLS; GENETICS; ETIOLOGY; STRESS;
D O I
10.1111/jpi.12203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.
引用
收藏
页码:173 / 177
页数:5
相关论文
共 50 条
  • [31] The pathology of primary progressive multiple sclerosis
    Brück, W
    Lucchinetti, C
    Lassmann, H
    MULTIPLE SCLEROSIS, 2002, 8 (02): : 93 - 97
  • [32] Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report
    Ostojic, Sergej M.
    Ostojic, Jelena
    Zanini, Dragana
    Jezdimirovic, Tatjana
    Stajer, Valdemar
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (01)
  • [33] The search for responsive clinical endpoints in primary progressive multiple sclerosis
    Bosma, L. V. A. E.
    Kragt, J. J.
    Brieva, L.
    Khaleeli, Z.
    Montalban, X.
    Polman, C. H.
    Thompson, A. J.
    Tintore, M.
    Uitdehaag, B. M. J.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (06) : 715 - 720
  • [34] Biomarkers of disability worsening in inactive primary progressive multiple sclerosis
    Baeva, Maria-Elizabeth
    Tottenham, Isabelle
    Koch, Marcus
    Camara-Lemarroy, Carlos
    JOURNAL OF NEUROIMMUNOLOGY, 2024, 387
  • [35] Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis
    Kaasinen, Valtteri
    Joutsa, Juho
    Rissanen, Eero
    Airas, Laura
    Soilu-Hanninen, Merja
    Noponen, Tommi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [36] Machine learning-based prediction of disease progression in primary progressive multiple sclerosis
    Gurevich, Michael
    Zilkha-Falb, Rina
    Sherman, Jia
    Usdin, Maxime
    Raposo, Catarina
    Craveiro, Licinio
    Sonis, Polina
    Magalashvili, David
    Menascu, Shay
    Dolev, Mark
    Achiron, Anat
    BRAIN COMMUNICATIONS, 2025, 7 (01)
  • [37] Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis
    Blok, Katelijn M.
    van Rosmalen, Joost
    Tebayna, Nura
    Smolders, Joost
    Wokke, Beatrijs
    de Beukelaar, Janet
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [38] Interferon Beta for Primary Progressive Multiple Sclerosis
    Ignacio Rojas, Juan
    Romano, Marina
    Ciapponi, Agustin
    Patrucco, Liliana
    Cristiano, Edgardo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [39] The MRZ reaction in primary progressive multiple sclerosis
    Hottenrott, Tilman
    Dersch, Rick
    Berger, Benjamin
    Rauer, Sebastian
    Huzly, Daniela
    Stich, Oliver
    FLUIDS AND BARRIERS OF THE CNS, 2017, 14
  • [40] Immunologic factors in primary progressive multiple sclerosis
    Hohlfeld, R
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 : S16 - S21